Illumina Reserved in Comments on PacBio Deal, Forthcoming on Qiagen Deal and New Products – GenomeWeb

NEW YORK Illumina officials were muted in their response to a threat from UK regulators that could potentially kill the firm's planned $1.2 billion acquisition of Pacific Biosciences. But that was just one of the storylines running through and around the firm's conference call following the release of its third quarter financial results.

"While we're still in the process of reviewing the documents, we continue to believe this acquisition is pro-competitive and in the best interests of customers and the genomics industry," Illumina CEO Francis deSouza said.

GenomeWeb Premium gives you: Full site access Interest-based email alerts Access to archives Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?Login Now.

*Before your trial expires, well put together a custom quote with your long-term premium options.

View post:
Illumina Reserved in Comments on PacBio Deal, Forthcoming on Qiagen Deal and New Products - GenomeWeb